BIONXT SOLUTIONS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 CAD | +11.11% |
|
+1.27% | -17.53% |
| Apr. 26 | BioNxt Solutions Inc. Announces ODF Cladribine Update | CI |
| Apr. 26 | BioNxt Solutions Inc. announced that it expects to receive CAD 1.62 million in funding | CI |
| Sales 2022 | 0.3 0.41 | Sales 2023 | 0.37 0.51 | Capitalization | 52.06M 71.17M |
|---|---|---|---|---|---|
| Net income 2022 | -12M -16.4M | Net income 2023 | -7M -9.57M | EV / Sales 2022 | 195,159,524 x |
| Net Debt 2022 | 4.23M 5.79M | Net Debt 2023 | 4.53M 6.19M | EV / Sales 2023 | 152,035,600 x |
| P/E ratio 2022 |
-3.99
x | P/E ratio 2023 |
-6.24
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.75% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +11.11% | ||
| 1 week | +1.27% | ||
| Current month | -14.89% | ||
| 1 month | -20.00% | ||
| 3 months | -40.30% | ||
| 6 months | +60.00% | ||
| Current year | -17.53% |
1 week
0.36
0.40
1 month
0.000.53
Current year
0.000.75
1 year
0.000.75
3 years
0.002.58
5 years
0.003.55
10 years
0.003.55
| Managers | Title | Age | Since |
|---|---|---|---|
Hugh Rogers
CEO | Chief Executive Officer | 44 | 17-12-11 |
P. Meagher
DFI | Director of Finance/CFO | 39 | 21-11-18 |
Wolfgang Probst
BRD | Director/Board Member | 43 | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
P. Meagher
DFI | Director of Finance/CFO | 39 | 21-11-18 |
Hugh Rogers
CEO | Chief Executive Officer | 44 | 17-12-11 |
Raimar Löbenberg
BRD | Director/Board Member | 58 | 18-12-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.4 | +11.11% | 12,500 |
| 24-04-23 | 0.36 | 0.00% | 10,500 |
| 24-04-22 | 0.36 | -8.86% | 6,000 |
Delayed Quote Canadian Securities Exchange, April 26, 2024 at 11:14 am EDT
More quotes
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany. The Company is also focused on regulatory approval and commercialization of medical products for European markets. The Company, through its subsidiary, 3a-diagnostics GmbH, offers diagnostic products, which include COVID-19 PCR Diagnostic Kit and Peri-Implantitis Oral Biosensor.
Sector
Pharmaceuticals
Calendar
2024-05-27
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.53% | 32M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BNXT Stock
